Search research articles
Contact Us
Filters
Showing results (1-10 of 28) with videos related to
Page
of 3
Sort By:
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|
June 17, 2004
Second-generation antipsychotics: looking beyond efficacy
A George Awad
Journal of Psychopharmacology (Oxford, England)
|
December 16, 2011
Is it time to consider comorbid substance abuse as a new indication for antipsychotic drug development?
A George Awad
Journal of Psychiatry & Neuroscience : JPN
|
May 16, 2006
The rational use of medications in acute psychotic presentations -- the case for less is more
A George Awad
Expert Review of Pharmacoeconomics & Outcomes Research
|
August 21, 2015
'The patient': at the center of patient-reported outcomes
A George Awad
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 1, 2011
Quality-of-life assessment in schizophrenia: the unfulfilled promise
A George Awad
CNS Drugs
|
December 5, 2018
Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later
A George Awad
Expert Review of Pharmacoeconomics & Outcomes Research
|
February 4, 2010
Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disorders
A George Awad
Acta Psychiatrica Scandinavica. Supplementum
|
May 10, 2005
Neuroleptic dysphoria 50 years later
A George Awad, Dieter Naber
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|
June 17, 2004
Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects?
Lakshmi P Voruganti, A George Awad
Pharmacoeconomics
|
January 18, 2008
The burden of schizophrenia on caregivers: a review
A George Awad, Lakshmi N P Voruganti
Page
of 3
Search research articles
Search
Showing results (1-10 of 28) with videos related to
Sort By:
Page
of 3
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|
June 17, 2004
Second-generation antipsychotics: looking beyond efficacy
A George Awad
Journal of Psychopharmacology (Oxford, England)
|
December 16, 2011
Is it time to consider comorbid substance abuse as a new indication for antipsychotic drug development?
A George Awad
Journal of Psychiatry & Neuroscience : JPN
|
May 16, 2006
The rational use of medications in acute psychotic presentations -- the case for less is more
A George Awad
Expert Review of Pharmacoeconomics & Outcomes Research
|
August 21, 2015
'The patient': at the center of patient-reported outcomes
A George Awad
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 1, 2011
Quality-of-life assessment in schizophrenia: the unfulfilled promise
A George Awad
CNS Drugs
|
December 5, 2018
Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later
A George Awad
Expert Review of Pharmacoeconomics & Outcomes Research
|
February 4, 2010
Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disorders
A George Awad
Acta Psychiatrica Scandinavica. Supplementum
|
May 10, 2005
Neuroleptic dysphoria 50 years later
A George Awad, Dieter Naber
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|
June 17, 2004
Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects?
Lakshmi P Voruganti, A George Awad
Pharmacoeconomics
|
January 18, 2008
The burden of schizophrenia on caregivers: a review
A George Awad, Lakshmi N P Voruganti
Page
of 3